Lactate Dehydrogenase Test · Blood

If cells anywhere in your body are being damaged faster than normal, whether by a heart attack, a growing tumor, an aggressive infection, or even the quiet destruction of red blood cells, one number on your lab panel will almost always move: LDH (lactate dehydrogenase). It is not specific to any single organ. That is actually its strength. It functions like a body-wide alarm that goes off whenever cells are breaking down, and the higher it climbs, the more serious the damage tends to be.

In a study of over 8,000 heart failure patients, those in the highest LDH quarter had roughly 50% greater risk of a heart failure event or cardiovascular death compared to those in the lowest quarter, after accounting for other risk factors. In hospitalized COVID-19 patients, elevated LDH at admission was associated with about a 6-fold higher chance of severe disease and roughly a 16-fold higher chance of dying. These are big signals from a test that costs a few dollars.

What LDH Actually Is

LDH is an enzyme that sits inside the fluid of almost every cell, helping convert sugar into energy. Specifically, it handles the back-and-forth conversion between two molecules, pyruvate and lactate, that your cells produce during the energy-making process called glycolysis. Under normal conditions, very little LDH leaks into your blood. When cells are injured, stressed, or dying, their membranes break open and LDH pours out.

Your body actually makes five slightly different versions of LDH, called isoenzymes, numbered LDH-1 through LDH-5. Each version is concentrated in different tissues. LDH-1 is most abundant in the heart and red blood cells. LDH-3 dominates in the lungs. LDH-5 is concentrated in the liver and skeletal muscle. When your doctor orders a total LDH, the test sums all five together. If needed, isoenzyme testing can help narrow down which organ is the source of the elevation.

Heart Disease Risk

LDH is one of the classic markers of heart muscle injury. In a study of 685 elderly patients who had a heart attack, those with high baseline LDH were about 3.6 times more likely to develop heart failure during follow-up, and their heart's pumping ability declined more steeply than in patients with lower LDH. This association held after adjusting for other markers of heart damage.

The signal extends beyond acute heart attacks. In the GALACTIC-HF trial of 8,179 patients with heart failure and reduced pumping function, LDH was measured in quartiles with medians at roughly 155, 183, 207, and 253 U/L. Risk rose steadily across those quartiles: patients in the top quarter had about 84% higher risk of a heart failure hospitalization or cardiovascular death compared to the bottom quarter before adjustments, and about 51% higher risk after accounting for other clinical factors.

If your LDH is persistently elevated and you have any cardiac risk factors, ordering a high-sensitivity troponin and a test called NT-proBNP (N-terminal pro-B-type natriuretic peptide, a protein that rises when the heart is under strain) can help determine whether your heart is the source.

Cancer and Tumor Burden

Tumors are metabolically greedy. They burn through sugar at high rates, even when oxygen is available, a phenomenon called the Warburg effect. This heavy sugar metabolism keeps LDH busy, and as tumor cells outgrow their blood supply and die, LDH floods the bloodstream. The result: LDH is one of the most consistent predictors of patient outcomes across many cancer types.

A meta-analysis of 38 studies covering 9,813 patients with metastatic prostate cancer found that high LDH roughly doubled the risk of death and increased the risk of disease progression by about 60%. In 29 studies of 6,629 kidney cancer patients, elevated LDH was similarly associated with about twice the mortality risk. In advanced melanoma patients receiving immunotherapy, those with high pretreatment LDH had about 2.4 times the mortality risk compared to those with normal levels.

A large Swedish registry study of 7,895 people who were eventually diagnosed with cancer found that LDH measured before the cancer was even detected predicted survival afterward. Those with LDH above the lab's upper limit of normal in the three years before diagnosis had roughly 85% higher risk of dying from their cancer.

For anyone being monitored for cancer, LDH is a cheap and widely available way to track tumor activity over time. A rising LDH during treatment is a concerning sign, while a falling LDH often signals that therapy is working.

Stroke and Brain Injury

When brain tissue is deprived of blood flow during a stroke, the damaged cells release LDH just like any other injured tissue. In a study of 732 acute ischemic stroke patients, higher admission LDH independently predicted worse outcomes and death over the following 3 to 18 months, even after adjusting for stroke severity scores and other clinical variables.

A separate study of 3,524 patients with aneurysmal subarachnoid hemorrhage (bleeding around the brain from a ruptured blood vessel) found that patients in the highest LDH quarter at admission had about 72% higher long-term mortality than those in the lowest quarter. Adding LDH to an established prediction model improved its accuracy.

Hemolytic Conditions and Sickle Cell Disease

Red blood cells are packed with LDH-1, so when red cells break apart faster than normal, a process called hemolysis, LDH rises sharply. In sickle cell disease, a study of 213 patients identified a distinct subgroup with high LDH who had significantly worse outcomes: higher rates of pulmonary hypertension (high blood pressure in the lungs), leg ulcers, priapism (painful, prolonged erections), and earlier death. The high-LDH group had evidence of more severe red cell destruction and blood vessel dysfunction.

If your LDH is elevated and your doctor suspects hemolysis, companion tests like haptoglobin (a protein that binds free hemoglobin and drops during hemolysis), reticulocyte count (young red blood cells, which rise when the body tries to replace destroyed ones), and indirect bilirubin help confirm whether red blood cell destruction is the cause.

Infections and Critical Illness

During severe infections, cells throughout the body sustain damage from the infection itself, the immune response, and reduced blood flow to tissues. In a nationwide study of over 103,000 hospitalized patients with infections, LDH was categorized into four tiers. Compared to patients with LDH below 480 U/L, those with levels between 480 and 700 had about 1.8 times the mortality risk. Between 700 and 900, the risk roughly tripled. Above 900 U/L, mortality risk was about 3.7 times higher. These associations were similar regardless of whether the infection was in the lungs or elsewhere.

During the COVID-19 pandemic, LDH became one of the most reliable early warning signs. A pooled analysis of 1,532 hospitalized patients found that elevated LDH at admission was linked to approximately 6 times the odds of progressing to severe disease. A separate analysis estimated an almost 12-fold increase in risk. Even among patients who started with mild COVID-19, those with higher LDH at baseline were significantly more likely to deteriorate.

Lung Function

A study of 3,453 adults from the NHANES database (a large, nationally representative health survey in the United States) found that higher serum LDH was linearly associated with lower lung function, as measured by how forcefully and completely a person could exhale. This association held after adjusting for age, sex, smoking, and other factors, suggesting that chronic, low-grade tissue stress in the lungs may contribute to LDH elevations even outside of acute illness.

Reference Ranges

LDH reference ranges vary between labs because different assay methods and reagents produce slightly different numbers. Most adult reference ranges cluster around 120 to 250 U/L, with the upper limit of normal typically set between 240 and 255 U/L. The ranges below reflect values commonly used across major clinical studies and should be treated as general orientation, not absolute cutoffs. Always compare your results within the same lab over time.

In heart failure patients, risk increased across quartiles starting at a median of just 155 U/L, well within the conventional normal range. This means that even modest increases over your personal baseline can carry clinical meaning, especially if they persist.

When Results Can Be Misleading

Because LDH sits inside so many different cell types, many situations can push it up temporarily without signaling the kind of chronic damage you are trying to detect. Keep these in mind before acting on a single reading.

• Intense exercise: Skeletal muscle is rich in LDH-5. A hard workout, especially one that causes noticeable muscle soreness, can spike LDH for 24 to 72 hours. Avoid vigorous exercise for at least 48 hours before your blood draw.
• Acute illness or recent surgery: Any infection, fever, or surgical procedure can elevate LDH for days to weeks afterward. If you have been sick recently, note that on your lab order so the result can be interpreted correctly.
• Sample handling errors: If the blood sample is drawn roughly, shipped in extreme temperatures, or processed too slowly, red blood cells in the tube can burst (a problem called hemolysis), releasing their LDH-1 into the sample and producing a falsely high result. If your LDH is unexpectedly elevated and nothing else on your panel supports it, ask your lab whether the sample showed signs of hemolysis.
• Medications that cause real tissue injury: Some chemotherapy drugs, certain antibiotics, and drugs that can damage the liver or kidneys may raise LDH by genuinely injuring cells. This is not an artifact; it reflects actual drug-induced harm. If you start a new medication and your LDH rises, this is worth investigating.

Tracking Your Trend

A single LDH reading is a snapshot, and snapshots can be misleading. The real value of LDH lies in watching it over time. In metastatic breast cancer, patients whose LDH normalized after 12 weeks of treatment had significantly better survival than those whose LDH stayed high or rose. In advanced lung cancer, patients whose LDH remained elevated at 6 weeks of treatment had about twice the mortality risk of those whose LDH fell. The direction and speed of change often carry more information than any single number.

LDH is most powerful when combined with other markers. Paired with troponin, it adds predictive value for cardiac events. Paired with haptoglobin and bilirubin, it helps diagnose hemolysis. Paired with tumor markers and imaging, it tracks cancer burden. On its own, it raises the right questions. Companion tests provide the answers.